MCID: RSP002
MIFTS: 54

Respiratory Syncytial Virus Infectious Disease

Categories: Infectious diseases

Aliases & Classifications for Respiratory Syncytial Virus Infectious Disease

MalaCards integrated aliases for Respiratory Syncytial Virus Infectious Disease:

Name: Respiratory Syncytial Virus Infectious Disease 12
Respiratory Syncytial Virus Infections 44 72
Respiratory Syncytial Virus Infection 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1273
MeSH 44 D018357
NCIt 50 C3354
SNOMED-CT 68 55735004
UMLS 72 C0035235

Summaries for Respiratory Syncytial Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in infection located in upper respiratory tract or located in lower respiratory tract, has material basis in Human respiratory syncytial virus, which is transmitted by droplet spread of nasal secretions from an infected person while coughing or sneezing, or transmitted by contaminated fomites. The infection has symptom runny nose, has symptom fever, has symptom cough, has symptom wheezing, and has symptom respiratory distress.

MalaCards based summary : Respiratory Syncytial Virus Infectious Disease, also known as respiratory syncytial virus infections, is related to cytokine deficiency and bronchiolitis, and has symptoms including fever, respiratory distress and cough. An important gene associated with Respiratory Syncytial Virus Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Palivizumab and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and bone, and related phenotypes are hematopoietic system and immune system

Related Diseases for Respiratory Syncytial Virus Infectious Disease

Diseases related to Respiratory Syncytial Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 cytokine deficiency 31.8 IL5 IL13
2 bronchiolitis 31.3 IL5 IL13 CCL5 CCL3
3 ige responsiveness, atopic 31.1 IL5 IL13
4 pulmonary eosinophilia 31.0 IL5 IL13 CCL5
5 conjunctivitis 31.0 IL5 IL13
6 rhinitis 30.9 IL5 IL13 CCL5
7 allergic asthma 30.8 IL5 IL13 CCL5
8 respiratory allergy 30.6 IL5 IL13
9 upper respiratory tract disease 30.6 IL5 IL13 CCL5
10 pollen allergy 30.6 IL5 IL13
11 dermatitis, atopic 30.5 IL5 IL13 CCL5
12 allergic conjunctivitis 30.5 IL5 IL13
13 common cold 30.4 IL5 IL13 CCL5
14 allergic hypersensitivity disease 30.4 IL5 IL13 CCL5
15 pulmonary disease, chronic obstructive 30.4 SFTPB IL13 CCL5
16 lung disease 30.3 SFTPB IL5 IL13 CCL5 CCL3
17 parainfluenza virus type 3 30.3 NEU1 IFNB1
18 bronchial disease 30.2 IL5 IL13 CCL5
19 japanese encephalitis 30.2 IFNB1 CCL5
20 asthma 30.0 IL5 IL13 CCL5 CCL3
21 severe acute respiratory syndrome 30.0 IFNB1 CCL5
22 proteasome-associated autoinflammatory syndrome 1 30.0 IL5 IL13 CCL5 CCL3
23 newcastle disease 29.6 NEU1 IFNB1
24 pneumonia 29.5 SFTPB IL5 IL13 CCL5 CCL3
25 viral infectious disease 29.5 IRF1 IFNB1 CCL5 CCL3
26 pulmonary fibrosis, idiopathic 29.3 SFTPB IL13 CCL5 CCL3
27 bronchopulmonary dysplasia 10.9
28 hypotrichosis and recurrent skin vesicles 10.8
29 hypereosinophilic syndrome 10.8
30 respiratory failure 10.7
31 otitis media 10.7
32 bronchitis 10.7
33 cystic fibrosis 10.6
34 vaccinia 10.6
35 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.5
36 bacterial infectious disease 10.5
37 lymphopenia 10.5
38 haemophilus influenzae 10.5
39 bronchiolitis obliterans 10.5
40 keratoconjunctivitis 10.5 IL5 IL13
41 viral pneumonia 10.5
42 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL5 IL13
43 nickel allergic contact dermatitis 10.4 IL5 IL13
44 paragonimiasis 10.4 IL5 IL13
45 chronic eosinophilic pneumonia 10.4 IL5 CCL5
46 inflammatory bowel disease 4 10.4 IL5 IL13
47 down syndrome 10.4
48 encephalopathy 10.4
49 hematopoietic stem cell transplantation 10.4
50 status asthmaticus 10.4 IL5 CCL5

Graphical network of the top 20 diseases related to Respiratory Syncytial Virus Infectious Disease:



Diseases related to Respiratory Syncytial Virus Infectious Disease

Symptoms & Phenotypes for Respiratory Syncytial Virus Infectious Disease

Symptoms:

12
  • fever
  • respiratory distress
  • cough
  • wheezing
  • runny nose

UMLS symptoms related to Respiratory Syncytial Virus Infectious Disease:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Respiratory Syncytial Virus Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.43 CCL5 IFNB1 IL13 IL5 IRF1 NEU1
2 immune system MP:0005387 9.1 CCL5 IFNB1 IL13 IL5 IRF1 NEU1

Drugs & Therapeutics for Respiratory Syncytial Virus Infectious Disease

Drugs for Respiratory Syncytial Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
2
Ribavirin Approved Phase 3 36791-04-5 37542
3 Calamus Phase 3
4 Antibodies, Monoclonal Phase 2, Phase 3
5 Antineoplastic Agents, Immunological Phase 2, Phase 3
6 Antiviral Agents Phase 3
7 Anti-Infective Agents Phase 3
8 Pharmaceutical Solutions Phase 3
9 Antimetabolites Phase 3
10
Coal tar Approved Phase 2 8007-45-2
11
tannic acid Approved Phase 2 1401-55-4
12
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
13
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
14
Histidine Approved, Nutraceutical Phase 2 71-00-1 6274
15 PC786 Phase 2
16
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
17
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
18
Itraconazole Approved, Investigational Phase 1 84625-61-6 55283
19
Rifampicin Approved Phase 1 13292-46-1 5381226 5458213
20
Verapamil Approved Phase 1 52-53-9 2520
21
Prednisone Approved, Vet_approved Phase 1 53-03-2 5865
22
Quinidine Approved, Investigational Phase 1 56-54-2 441074
23
Calcium Approved, Nutraceutical Phase 1 7440-70-2 271
24
BCG vaccine Investigational Phase 1
25 Adjuvants, Immunologic Phase 1
26 Neurotransmitter Agents Phase 1
27 14-alpha Demethylase Inhibitors Phase 1
28 Cytochrome P-450 CYP3A Inducers Phase 1
29 Tranquilizing Agents Phase 1
30 Cytochrome P-450 CYP3A Inhibitors Phase 1
31 Cytochrome P-450 Enzyme Inducers Phase 1
32 Antifungal Agents Phase 1
33 Hormones Phase 1
34 Anti-Anxiety Agents Phase 1
35 GABA Agents Phase 1
36 Adjuvants, Anesthesia Phase 1
37 Steroid Synthesis Inhibitors Phase 1
38 Cytochrome P-450 Enzyme Inhibitors Phase 1
39 Anti-Bacterial Agents Phase 1
40 Antitubercular Agents Phase 1
41
Hydroxyitraconazole Phase 1
42 Hormone Antagonists Phase 1
43 Central Nervous System Depressants Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 1
45 Hypnotics and Sedatives Phase 1
46 Antibiotics, Antitubercular Phase 1
47 Anti-Arrhythmia Agents Phase 1
48 Anesthetics Phase 1
49 GABA Modulators Phase 1
50 Anesthetics, General Phase 1

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
2 Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed NCT01466062 Phase 3 Palivizumab
3 A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation Completed NCT01006629 Phase 2, Phase 3
4 A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children Completed NCT00129766 Phase 3
5 Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study Completed NCT03171142 Phase 3 Heliox;Air
6 A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants Completed NCT02624947 Phase 3
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants Completed NCT02325791 Phase 3 Suptavumab 30 mg/kg;Placebo Matched to Suptavumab;Suptavumab 30 mg/kg- 1 Dose;Suptavumab 30 mg/kg - 2 Doses
8 A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY) Recruiting NCT03959488 Phase 2, Phase 3 MEDI8897;Palivizumab
9 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) Recruiting NCT03979313 Phase 3 MEDI8897;Placebo
10 A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient Terminated NCT00031473 Phase 3 Virazole (Ribavirin) Inhalation Solution
11 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model Completed NCT02094365 Phase 2 ALS-008176;vehicle
12 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model Completed NCT03258502 Phase 2 RV521;Placebo
13 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model Completed NCT02718937 Phase 2 BTA-C585 oral capsule;Matching placebo capsules
14 An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults Completed NCT03334695 Phase 2 Placebo
15 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Completed NCT02135614 Phase 2 Presatovir;Presatovir placebo
16 A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care. Completed NCT02309320 Phase 1, Phase 2
17 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Completed NCT02254421 Phase 2 Presatovir;Placebo
18 A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects Completed NCT02387606 Phase 2 Placebo;JNJ-53718678
19 A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection Completed NCT02654171 Phase 2 AK0529;Placebo
20 Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain) Completed NCT01756482 Phase 2 GS-5806;Placebo
21 A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age Completed NCT01960686 Phase 2
22 A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness Completed NCT02673476 Phase 2 ALS-008176;Placebo
23 A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus Completed NCT00496821 Phase 2 ALN-RSV01
24 A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT00658086 Phase 2 ALN-RSV01;normal saline
25 A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT01065935 Phase 2 ALN-RSV01;Normal Saline
26 An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women Completed NCT02753413 Phase 2
27 A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model Completed NCT03382431 Phase 1, Phase 2 PC786;Placebo/vehicle
28 A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life Completed NCT02247726 Phase 2 Saline Placebo (0.5mL injection);RSV F vaccine (0.5mL injection)
29 An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women Completed NCT02360475 Phase 2
30 A Phase 1/2, Open-Label, Repeat-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children at Risk for Serious RSV Disease Completed NCT00192478 Phase 1, Phase 2
31 A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine Completed NCT02873286 Phase 2
32 A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation Completed NCT00232635 Phase 2 A-60444
33 A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants Completed NCT02878330 Phase 2 MEDI8897;Placebo
34 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract Completed NCT02254408 Phase 2 Presatovir;Placebo
35 A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season Completed NCT00316264 Phase 2
36 An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women Completed NCT02956837 Phase 2 Placebo (Formulation buffer S9b)
37 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model. Recruiting NCT03691623 Phase 2 EDP-938 Dose 1;EDP-938 Dose 2;Placebo;EDP-938 Dose 3;EDP-938 Dose 4;Placebo
38 A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Orally Administered AK0529 in Adults With Respiratory Syncytial Virus Infection Recruiting NCT03699202 Phase 2 AK0529;Placebo
39 A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection Recruiting NCT03656510 Phase 2 JNJ-53718678;Placebo
40 A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus Recruiting NCT03379675 Phase 2 JNJ-53718678 500 mg;JNJ-53718678 80 mg;Placebo
41 A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection Active, not recruiting NCT03332459 Phase 2 Lumicitabine;Placebo
42 A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants Active, not recruiting NCT02927873 Phase 2 Placebo LD;Placebo MD;Placebo HD
43 An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant Active, not recruiting NCT01502072 Phase 2 Ribavirin;Ribavirin
44 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Not yet recruiting NCT04056611 Phase 2 JNJ-53718678;Placebo
45 A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients Terminated NCT03715023 Phase 2 PC786;Placebo;SOC
46 An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers Withdrawn NCT03191383 Phase 2 Placebo (Formulation buffer S9b)
47 A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age Unknown status NCT03213405 Phase 1
48 A Phase I, Single-centre, Open Label Study to Evaluate the Potential Occurrence, Reversibility and Prevention of Bronchoconstriction as Individual Response to Escalating Doses Followed by Repeated Doses of ALX-0171, Administered by Oral Inhalation to Adults With Hyperresponsive Airways Completed NCT01909843 Phase 1
49 A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of 14C-ALS-008176 in Healthy Male Subjects Completed NCT02231671 Phase 1 ALS-008176;ALS-008112
50 A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing, Multiple Ascending Dosing and Food-effect in Healthy Volunteers Completed NCT01906164 Phase 1 ALS-008176;Placebo

Search NIH Clinical Center for Respiratory Syncytial Virus Infectious Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Immunoglobulins, Intravenous
palivizumab
Palivizumab
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
Ribavirin

Cochrane evidence based reviews: respiratory syncytial virus infections

Genetic Tests for Respiratory Syncytial Virus Infectious Disease

Anatomical Context for Respiratory Syncytial Virus Infectious Disease

MalaCards organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

41
Testes, Lung, Bone, Bone Marrow, Neutrophil, Heart, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

19
Upper Respiratory Tract, Lower Respiratory Tract

Publications for Respiratory Syncytial Virus Infectious Disease

Articles related to Respiratory Syncytial Virus Infectious Disease:

(show top 50) (show all 415)
# Title Authors PMID Year
1
Antiviral drugs: current state of the art. 9 38
11418355 2001
2
Delayed Diagnosis of Respiratory Syncytial Virus Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the United States. 38
31070757 2019
3
Acute Encephalitis and Myocarditis Associated with Respiratory Syncytial Virus Infections. 38
31380518 2019
4
What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections? 38
31158780 2019
5
Genomic analysis of respiratory syncytial virus infections in households and utility in inferring who infects the infant. 38
31296922 2019
6
Comparison of Clinical Characteristics of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Young Children. 38
30814460 2019
7
Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. 38
31221784 2019
8
Ten years of severe respiratory syncytial virus infections in a tertiary paediatric intensive care unit. 38
31095832 2019
9
Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. 38
31143074 2019
10
Respiratory viruses in adults hospitalised with Community-Acquired Pneumonia during the non-winter months in Melbourne: Routine diagnostic practice may miss large numbers of influenza and respiratory syncytial virus infections. 38
30982246 2019
11
Seasonal variation in childhood mortality. 38
30880511 2019
12
Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali. 38
30810160 2019
13
Notes from the Field: Respiratory Syncytial Virus Infections in a Neonatal Intensive Care Unit - Louisiana, December 2017. 38
30629570 2019
14
Burden of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Asthmatic Children. 38
29742646 2018
15
Respiratory syncytial virus infections in India: Epidemiology and need for vaccine. 38
30880691 2018
16
Oral versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplantation Recipients. 38
30202920 2018
17
Respiratory syncytial virüs infections in neonates and infants. 38
30116126 2018
18
Immunization during pregnancy. 38
29715051 2018
19
Case study-based time-course analysis of symptoms of respiratory syncytial virus infections followed by acute sinusitis in otherwise-healthy adults. 38
29997985 2018
20
Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. 38
29360277 2018
21
Dose-dependent relationships between weight status and clinical outcomes among infants hospitalized with respiratory syncytial virus infections. 38
29359458 2018
22
Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections. 38
29463335 2018
23
Respiratory Tract Infections and Voice Quality in 4-Year-old Children in the STEPS Study. 38
29506899 2018
24
Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan. 38
29746578 2018
25
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. 38
29168012 2018
26
A Two-Dimensional Human Minilung System (Model) for Respiratory Syncytial Virus Infections. 38
29232863 2017
27
Elucidation of Bacterial Pneumonia-Causing Pathogens in Patients with Respiratory Viral Infection. 38
28905531 2017
28
Replication defective viral genomes exploit a cellular pro-survival mechanism to establish paramyxovirus persistence. 38
28986577 2017
29
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. 38
28926860 2017
30
The Burden of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Norwegian Children. 38
28838133 2017
31
Maternal immunisation: collaborating with mother nature. 38
28433705 2017
32
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. 38
28187116 2017
33
In Reply: Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. 38
28187117 2017
34
Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. 38
27439650 2017
35
The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children. 38
27738053 2017
36
Effect of climate on incidence of respiratory syncytial virus infections in a refugee camp in Kenya: A non-Gaussian time-series analysis. 38
28570627 2017
37
[Human Metapneumovirus Infection]. 38
30609459 2016
38
Approved Antiviral Drugs over the Past 50 Years. 38
27281742 2016
39
Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. 38
27078122 2016
40
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. 38
27439110 2016
41
Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts. 38
27314379 2016
42
Cytokine responses in primary and secondary respiratory syncytial virus infections. 38
26882371 2016
43
Reduced Expression of HLA-DR on Monocytes During Severe Respiratory Syncytial Virus Infections. 38
26658377 2016
44
Development of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats. 38
27224021 2016
45
Burden of respiratory syncytial virus infections in China: Systematic review and meta-analysis. 38
26682049 2015
46
Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household Cohort. 38
25941331 2015
47
Clinical and laboratory characteristics of viral lower respiratory tract infections in preschool children. 38
26373742 2015
48
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). 38
26670908 2015
49
High Viral Load and Respiratory Failure in Adults Hospitalized for Respiratory Syncytial Virus Infections. 38
25904604 2015
50
Respiratory syncytial virus infections in pediatric transplant recipients: A Canadian Paediatric Surveillance Program study. 38
26152857 2015

Variations for Respiratory Syncytial Virus Infectious Disease

Expression for Respiratory Syncytial Virus Infectious Disease

LifeMap Discovery
Genes differentially expressed in tissues of Respiratory Syncytial Virus Infectious Disease patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 6.10 0.000
2 OLFM4 olfactomedin 4 Blood + 5.54 0.000
3 PRTN3 proteinase 3 Blood + 5.47 0.000
4 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Blood + 5.04 0.000
5 MMP8 matrix metallopeptidase 8 Blood + 4.32 0.000
6 MPO myeloperoxidase Blood + 4.23 0.000
7 HP haptoglobin Blood + 4.21 0.000
8 CTSG cathepsin G Blood + 4.10 0.000
9 DEFA4 defensin, alpha 4, corticostatin Blood + 3.98 0.000
10 OTOF otoferlin Blood + 3.94 0.000
11 OLFM1 olfactomedin 1 Blood - 3.93 0.000
12 RETN resistin Blood + 3.90 0.000
13 ARG1 arginase 1 Blood + 3.89 0.000
14 GPR84 G protein-coupled receptor 84 Blood + 3.88 0.000
15 NOV nephroblastoma overexpressed Blood - 3.79 0.000
16 ELANE elastase, neutrophil expressed Blood + 3.76 0.000
17 RHAG Rh-associated glycoprotein Blood + 3.73 0.000
18 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Blood + 3.68 0.000
19 MAOA monoamine oxidase A Blood + 3.62 0.000
20 ZDHHC19 zinc finger, DHHC-type containing 19 Blood + 3.62 0.000
21 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 Blood + 3.55 0.000
22 KCNG1 potassium channel, voltage gated modifier subfamily G, member 1 Blood - 3.48 0.000
23 HBBP1 hemoglobin, beta pseudogene 1 Blood + 3.45 0.000
24 AZU1 azurocidin 1 Blood + 3.43 0.000
25 ANXA3 annexin A3 Blood + 3.42 0.000
26 COL17A1 collagen, type XVII, alpha 1 Blood + 3.39 0.000
27 CD177 CD177 molecule Blood + 3.38 0.000
28 PRSS33 protease, serine, 33 Blood - 3.36 0.000
29 METTL7B methyltransferase like 7B Blood + 3.33 0.000
30 GPR42 G protein-coupled receptor 42 (gene/pseudogene) Blood + 3.27 0.000
31 C1QC complement component 1, q subcomponent, C chain Blood + 3.24 0.000
32 KCTD14 potassium channel tetramerization domain containing 14 Blood + 3.22 0.000
33 DEFA3 defensin, alpha 3, neutrophil-specific Blood + 3.20 0.000
34 FGF9 fibroblast growth factor 9 Blood - 3.15 0.000
35 PTGDR2 prostaglandin D2 receptor 2 Blood - 3.15 0.000
36 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.13 0.000
37 ADGRE4P adhesion G protein-coupled receptor E4, pseudogene Blood - 3.11 0.000
38 MMP28 matrix metallopeptidase 28 Blood - 3.09 0.000
39 XK X-linked Kx blood group Blood + 3.08 0.000
40 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Blood + 3.04 0.000
41 KIF5C kinesin family member 5C Blood - 3.03 0.000
42 DLK1 delta-like 1 homolog (Drosophila) Blood + 3.01 0.000
43 LRRC26 leucine rich repeat containing 26 Blood - 3.01 0.000
44 LTF lactotransferrin Blood + 3.00 0.000
Search GEO for disease gene expression data for Respiratory Syncytial Virus Infectious Disease.

Pathways for Respiratory Syncytial Virus Infectious Disease

Pathways related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 NEU1 IRF1 IL5 IL13 IFNB1 CCL5
2
Show member pathways
13.21 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
3
Show member pathways
12.96 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
4
Show member pathways
12.14 IL5 IL13 IFNB1
5
Show member pathways
11.99 IRF1 IL5 IL13 IFNB1
6 11.75 IRF1 IFNB1 CCL5
7 11.71 IRF1 IFNB1 CCL3
8 11.55 IRF1 IL5 IL13
9 11.51 IL5 IL13 CCL3
10 11.43 IL13 CCL5 CCL3
11
Show member pathways
11.37 IRF1 IL5 IL13 CCL5 CCL3
12 11.27 IL5 IL13
13 11.19 IL13 CCL5 CCL3
14 11.16 IRF1 IFNB1
15 11.09 IL5 IL13
16 11.02 IRF1 IL13
17 10.98 IL5 IL13
18 10.94 IFNB1 CCL5
19 10.79 IL5 IL13 CCL5 CCL3
20 10.79 IL5 IL13 IFNB1
21 10.75 IL5 IL13 CCL5 CCL3
22 10.72 IL5 IL13 CCL5 CCL3

GO Terms for Respiratory Syncytial Virus Infectious Disease

Cellular components related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 SFTPB IL5 IL13 IFNB1 CCL5 CCL3
2 extracellular region GO:0005576 9.17 SFTPB NEU1 IL5 IL13 IFNB1 CCL5

Biological processes related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.69 IL5 CCL5 CCL3
2 immune response GO:0006955 9.67 IL5 IL13 CCL5 CCL3
3 type I interferon signaling pathway GO:0060337 9.6 IRF1 IFNB1
4 positive regulation of smooth muscle cell proliferation GO:0048661 9.59 IL13 CCL5
5 positive chemotaxis GO:0050918 9.58 CCL5 CCL3
6 monocyte chemotaxis GO:0002548 9.58 CCL5 CCL3
7 positive regulation of B cell proliferation GO:0030890 9.57 IL5 IL13
8 negative regulation of viral genome replication GO:0045071 9.56 IFNB1 CCL5
9 protein kinase B signaling GO:0043491 9.55 CCL5 CCL3
10 lymphocyte chemotaxis GO:0048247 9.54 CCL5 CCL3
11 lipopolysaccharide-mediated signaling pathway GO:0031663 9.52 CCL5 CCL3
12 positive regulation of JAK-STAT cascade GO:0046427 9.49 IL5 CCL5
13 positive regulation of calcium ion transport GO:0051928 9.48 CCL5 CCL3
14 positive regulation of innate immune response GO:0045089 9.46 IFNB1 CCL5
15 inflammatory response GO:0006954 9.46 IL5 IL13 CCL5 CCL3
16 eosinophil chemotaxis GO:0048245 9.43 CCL5 CCL3
17 cellular response to interferon-beta GO:0035458 9.4 IRF1 IFNB1
18 macrophage chemotaxis GO:0048246 9.32 CCL5 CCL3
19 negative regulation by host of viral transcription GO:0043922 9.26 CCL5 CCL3
20 cytokine-mediated signaling pathway GO:0019221 9.02 IL5 IL13 IFNB1 CCL5 CCL3
21 positive regulation of natural killer cell chemotaxis GO:2000503 8.96 CCL5 CCL3

Molecular functions related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL5 CCL3
2 chemoattractant activity GO:0042056 9.4 CCL5 CCL3
3 CCR chemokine receptor binding GO:0048020 9.37 CCL5 CCL3
4 cytokine receptor binding GO:0005126 9.32 IL13 IFNB1
5 CCR5 chemokine receptor binding GO:0031730 9.26 CCL5 CCL3
6 phospholipase activator activity GO:0016004 9.16 CCL5 CCL3
7 cytokine activity GO:0005125 9.02 IL5 IL13 IFNB1 CCL5 CCL3
8 CCR1 chemokine receptor binding GO:0031726 8.96 CCL5 CCL3

Sources for Respiratory Syncytial Virus Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....